Cargando…
Reviewing evidence of the clinical effectiveness of commercially available antivenoms in sub-Saharan Africa identifies the need for a multi-centre, multi-antivenom clinical trial
BACKGROUND: Snakebite envenoming kills more than more than 20,000 people in Sub-Saharan Africa every year. Poorly regulated markets have been inundated with low-price, low-quality antivenoms. This review aimed to systematically collect and analyse the clinical data on all antivenom products now avai...
Autores principales: | Potet, Julien, Smith, James, McIver, Lachlan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615628/ https://www.ncbi.nlm.nih.gov/pubmed/31233536 http://dx.doi.org/10.1371/journal.pntd.0007551 |
Ejemplares similares
-
Antivenom supply and demand: An analysis of antivenom availability and utilization in South Africa
por: Neumann, Natalie R, et al.
Publicado: (2023) -
Challenges and prospects of snake antivenom supply in sub-Saharan Africa
por: Habib, Abdulrazaq G., et al.
Publicado: (2020) -
Availability, accessibility and use of antivenom for snakebite envenomation in Africa with proposed strategies to overcome the limitations
por: Dalhat, Mahmood Muazu, et al.
Publicado: (2023) -
Use of antivenoms for the treatment of envenomation by Elapidae snakes in Guinea, Sub-Saharan Africa
por: Baldé, Mamadou C, et al.
Publicado: (2013) -
Antivenoms for Snakebite Envenoming: What Is in the Research Pipeline?
por: Alirol, Emilie, et al.
Publicado: (2015)